147 related articles for article (PubMed ID: 35585020)
1. Association between contralateral background parenchymal enhancement on MRI and outcome in patients with unilateral invasive breast cancer receiving neoadjuvant chemotherapy.
Rella R; Bufi E; Belli P; Scrofani AR; Petta F; Borghetti A; Marazzi F; Valentini V; Manfredi R
Diagn Interv Imaging; 2022 Oct; 103(10):486-494. PubMed ID: 35585020
[TBL] [Abstract][Full Text] [Related]
2. Association between background parenchymal enhancement and tumor response in patients with breast cancer receiving neoadjuvant chemotherapy.
Rella R; Bufi E; Belli P; Petta F; Serra T; Masiello V; Scrofani AR; Barone R; Orlandi A; Valentini V; Manfredi R
Diagn Interv Imaging; 2020 Oct; 101(10):649-655. PubMed ID: 32654985
[TBL] [Abstract][Full Text] [Related]
3. Background Parenchymal Enhancement on Preoperative Magnetic Resonance Imaging: Association With Recurrence-Free Survival in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
Choi JS; Ko ES; Ko EY; Han BK; Nam SJ
Medicine (Baltimore); 2016 Mar; 95(9):e3000. PubMed ID: 26945421
[TBL] [Abstract][Full Text] [Related]
4. Role of dynamic contrast-enhanced MRI in evaluating the association between contralateral parenchymal enhancement and survival outcome in ER-positive, HER2-negative, node-negative invasive breast cancer.
Shin GW; Zhang Y; Kim MJ; Su MY; Kim EK; Moon HJ; Yoon JH; Park VY
J Magn Reson Imaging; 2018 Dec; 48(6):1678-1689. PubMed ID: 29734483
[TBL] [Abstract][Full Text] [Related]
5. Relationship between background parenchymal enhancement on breast MRI and pathological tumor response in breast cancer patients receiving neoadjuvant chemotherapy.
Oh SJ; Chae EY; Cha JH; Shin HJ; Choi WJ; Kim HH
Br J Radiol; 2018 Jul; 91(1088):20170550. PubMed ID: 29848015
[TBL] [Abstract][Full Text] [Related]
6. Decreased background parenchymal enhancement of the contralateral breast after two cycles of neoadjuvant chemotherapy is associated with tumor response in HER2-positive breast cancer.
You C; Gu Y; Peng W; Li J; Shen X; Liu G; Peng W
Acta Radiol; 2018 Jul; 59(7):806-812. PubMed ID: 29065702
[TBL] [Abstract][Full Text] [Related]
7. Background parenchymal enhancement in the contralateral normal breast of patients undergoing neoadjuvant chemotherapy measured by DCE-MRI.
Chen JH; Yu H; Lin M; Mehta RS; Su MY
Magn Reson Imaging; 2013 Nov; 31(9):1465-71. PubMed ID: 23992630
[TBL] [Abstract][Full Text] [Related]
8. Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response.
Onishi N; Li W; Newitt DC; Harnish RJ; Strand F; Nguyen AA; Arasu VA; Gibbs J; Jones EF; Wilmes LJ; Kornak J; Joe BN; Price ER; Ojeda-Fournier H; Eghtedari M; Zamora KW; Woodard S; Umphrey HR; Nelson MT; Church AL; Bolan PJ; Kuritza T; Ward K; Morley K; Wolverton D; Fountain K; Lopez Paniagua D; Hardesty L; Brandt KR; McDonald ES; Rosen M; Kontos D; Abe H; Sheth D; Crane E; Dillis C; Sheth P; Hovanessian-Larsen L; Bang DH; Porter B; Oh KY; Jafarian N; Tudorica LA; Niell B; Drukteinis J; Newell MS; Giurescu ME; Berman E; Lehman CD; Partridge SC; Fitzpatrick KA; Borders MH; Yang WT; Dogan B; Goudreau SH; Chenevert T; Yau C; DeMichele A; Berry DA; Esserman LJ; Hylton NM
Radiology; 2021 Nov; 301(2):295-308. PubMed ID: 34427465
[TBL] [Abstract][Full Text] [Related]
9. Background parenchymal enhancement in breast MRI before and after neoadjuvant chemotherapy: correlation with tumour response.
Preibsch H; Wanner L; Bahrs SD; Wietek BM; Siegmann-Luz KC; Oberlecher E; Hahn M; Staebler A; Nikolaou K; Wiesinger B
Eur Radiol; 2016 Jun; 26(6):1590-6. PubMed ID: 26382845
[TBL] [Abstract][Full Text] [Related]
10. Ring Enhancement in Non-Neoplastic Breast Tissue on MRI During Neoadjuvant Chemotherapy for Breast Cancer: Incidence and Clinical Implications.
Oh J; Han BK; Ko EY; Ko ES; Choi JS; Kim H; Park YH; Kim JY
Acad Radiol; 2023 Dec; 30(12):2931-2939. PubMed ID: 37045651
[TBL] [Abstract][Full Text] [Related]
11. Quantitative background parenchymal enhancement to predict recurrence after neoadjuvant chemotherapy for breast cancer.
Moliere S; Oddou I; Noblet V; Veillon F; Mathelin C
Sci Rep; 2019 Dec; 9(1):19185. PubMed ID: 31844135
[TBL] [Abstract][Full Text] [Related]
12. Changes in background parenchymal enhancement in HER2-positive breast cancer before and after neoadjuvant chemotherapy: Association with pathologic complete response.
Dong JM; Wang HX; Zhong XF; Xu K; Bian J; Feng Y; Chen L; Zhang L; Wang X; Ma DJ; Wang B
Medicine (Baltimore); 2018 Oct; 97(43):e12965. PubMed ID: 30412117
[TBL] [Abstract][Full Text] [Related]
13. Association Between Background Parenchymal Enhancement and Pathologic Complete Remission Throughout the Neoadjuvant Chemotherapy in Breast Cancer Patients.
You C; Peng W; Zhi W; He M; Liu G; Xie L; Jiang L; Hu X; Shen X; Gu Y
Transl Oncol; 2017 Oct; 10(5):786-792. PubMed ID: 28806712
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of background parenchymal enhancement on breast magnetic resonance imaging for pathological tumor response to neoadjuvant chemotherapy in breast cancers: a systematic review.
Li X; Yan F
Cancer Imaging; 2024 Mar; 24(1):35. PubMed ID: 38462607
[TBL] [Abstract][Full Text] [Related]
15. The correlation of background parenchymal enhancement in the contralateral breast with patient and tumor characteristics of MRI-screen detected breast cancers.
Vreemann S; Gubern-Mérida A; Borelli C; Bult P; Karssemeijer N; Mann RM
PLoS One; 2018; 13(1):e0191399. PubMed ID: 29351560
[TBL] [Abstract][Full Text] [Related]
16. Background parenchymal enhancement: behavior during neoadjuvant chemotherapy for breast cancer and relationship with a pathological complete response.
Teixeira SRC; de Camargo Júnior HSA; Cabello C
Radiol Bras; 2020; 53(2):95-104. PubMed ID: 32336824
[TBL] [Abstract][Full Text] [Related]
17. MRI background parenchymal enhancement, fibroglandular tissue, and mammographic breast density in patients with invasive lobular breast cancer on adjuvant endocrine hormonal treatment: associations with survival.
Lo Gullo R; Daimiel I; Rossi Saccarelli C; Bitencourt A; Sevilimedu V; Martinez DF; Jochelson MS; Morris EA; Reiner JS; Pinker K
Breast Cancer Res; 2020 Aug; 22(1):93. PubMed ID: 32819432
[TBL] [Abstract][Full Text] [Related]
18. Effective factors to raise diagnostic performance of breast MRI for diagnosing pathologic complete response in breast cancer patients after neoadjuvant chemotherapy.
Choi BB; Kim SH
Acta Radiol; 2015 Jul; 56(7):790-7. PubMed ID: 24951616
[TBL] [Abstract][Full Text] [Related]
19. Background parenchymal enhancement on breast MRI and mammographic breast density: correlation with tumour characteristics.
Kim MY; Choi N; Yang JH; Yoo YB; Park KS
Clin Radiol; 2015 Jul; 70(7):706-10. PubMed ID: 25824280
[TBL] [Abstract][Full Text] [Related]
20. High-background parenchymal enhancement in the contralateral breast is an imaging biomarker for favorable prognosis in patients with triple-negative breast cancer treated with chemotherapy.
Xu C; Yu J; Wu F; Li X; Hu D; Chen G; Wu G
Am J Transl Res; 2021; 13(5):4422-4436. PubMed ID: 34150024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
